vTv Therapeutics Inc. (VTVT) - Dilution Analysis

10-Q filing | 3.9M shares outstanding

10-Q filing | 3.9M shares outstanding

S-3 filing: This prospectus relates to the offer and resale from time to time by the Selling Stockholders named in this prospectus of up to an aggregate of 15,876,640 shares of our Class A common stock, par value $0.01 per share.

10-Q filing | 2.6M shares outstanding

10-Q filing | 2.6M shares outstanding

10-K filing | 2.6M shares outstanding

10-Q filing | 2.6M shares outstanding

10-Q filing | 2.4M shares outstanding

10-Q filing | 2.4M shares outstanding

S-3 filing: vTv Therapeutics Inc. is offering up to $12,678,712 of its Class A common stock through an at-the-market offering with TD Cowen acting as sales agent.

10-K filing | 2.4M shares outstanding

8-K filing: Stock split 1-for-40 | Outstanding: 81,483,600 → 2,037,090

10-Q filing | 81.5M shares outstanding

10-Q filing | 81.5M shares outstanding

10-Q filing | 81.5M shares outstanding

10-K filing | 74.9M shares outstanding

10-Q filing | 80.5M shares outstanding

10-Q filing | 81.5M shares outstanding

8-K filing: vTv Therapeutics Inc. entered into a common stock purchase agreement with G42 Investments AI Holding RSC Ltd to sell 10,386,274 shares of Class A common stock at $2.41 per share for $25,000,000. ($25.0M proceeds)

10-Q filing | 54.1M shares outstanding

10-K filing | 66.9M shares outstanding

10-Q filing | 66.9M shares outstanding

10-Q filing | 60.2M shares outstanding

S-3 filing: This S-3 filing registers 9,437,376 shares of Class A common stock issuable pursuant to a purchase agreement with Lincoln Park Capital Fund, LLC, potentially generating up to $47,000,000 in gross proceeds for general corporate purposes.

10-Q filing | 58.0M shares outstanding

S-3/A filing: This S-3/A filing registers an indeterminate number of shares of Class A common stock with a proposed maximum aggregate offering price of $250,000,000, including unsold securities from a prior registration statement.

S-3 filing: The filing registers an indeterminate number of shares of Class A common stock with an aggregate initial offering price not to exceed $250,000,000, and terminates a previous offering of $230,999,999 of securities registered on Form S-3 (File No. 333-223269).

10-K filing | 57.6M shares outstanding

8-K filing: vTv Therapeutics Inc. sold 625,000 shares of Class A common stock to MacAndrews & Forbes Group LLC at a price of $1.60 per share, generating $1.0 million in proceeds. ($1.0M proceeds)

8-K filing: vTv Therapeutics Inc. sold 625,000 shares of Class A common stock to MacAndrews & Forbes Group LLC at a price of $1.60 per share for gross proceeds of $1.0 million. ($1.0M proceeds)

8-K filing: vTv Therapeutics Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, for the sale of up to $47,000,000 of Class A common stock, and also issued 425,725 shares of common stock to Lincoln Park as a commitment fee. Additionally, the company sold 625,000 shares of Class A common stock to MacAndrews & Forbes Group LLC for $1.60 per share. ($1.0M proceeds)

S-1 filing: This S-1 filing relates to the resale or other disposition from time to time of up to 5,331,306 shares of Class A common stock by Lincoln Park Capital Fund, LLC, issuable pursuant to a Purchase Agreement relating to the sale of up to $47,000,000 in shares of Class A common stock.

10-Q filing | 50.8M shares outstanding

8-K filing: vTv Therapeutics Inc. sold 3,847,405 shares of Class A common stock under the ATM Offering at then-market prices for total gross proceeds of approximately $10.2 million during the nine months ended September 30, 2020. ($10.2M proceeds)

10-Q filing | 48.0M shares outstanding

8-K filing: vTv Therapeutics Inc. sold 625,000 shares of its Class A common stock to MacAndrews & Forbes Group LLC at a price of $1.60 per share, resulting in gross proceeds of $1.0 million. ($1.0M proceeds)

10-Q filing | 44.7M shares outstanding

8-K filing: vTv Therapeutics Inc. sold 1,250,000 shares of Class A common stock to MacAndrews & Forbes Group LLC at a price of $1.60 per share, resulting in gross proceeds of $2.0 million. ($2.0M proceeds)

10-K filing | 42.2M shares outstanding

8-K filing: vTv Therapeutics Inc. sold 1,250,000 shares of Class A common stock to MacAndrews & Forbes Group LLC at a price of $1.60 per share, resulting in gross proceeds of $2.0 million. ($2.0M proceeds)

8-K filing: vTv Therapeutics Inc. sold 1,250,000 shares of Class A common stock to MacAndrews & Forbes Group LLC at a price of $1.60 per share, resulting in gross proceeds of $2.0 million. ($2.0M proceeds)